Miura Partners acquires HTBA: A Strategic Move in Natural Ingredients
Deal News | Nov 07, 2024 | Finance Community ES 2 - Corporate M&A
Miura Partners has acquired HealthTech BioActives (HTBA), an industry leader in the production and marketing of natural ingredients such as citrus flavonoids and a major European supplier of active forms of vitamin B12 for various sectors including pharmaceuticals, nutraceuticals, food and beverage, and animal nutrition. Based in Barcelona, Spain, HTBA has been innovating for over forty years and operates a state-of-the-art manufacturing plant in Murcia, Spain, and a Cincinnati, Ohio operations center, distributing to over 60 countries worldwide. The acquisition is backed by Miura IV fund, with a size of €475 million, marking Miura's third investment from this fund. Miura aims to drive both organic and inorganic growth initiatives for HTBA to establish it as a leading platform in the natural health and food ingredient sectors. The transaction is pending approval from Spanish regulators. KPMG Spain, Houlihan Lokey, and Bain & Company played advisory roles in the acquisition process.
Sectors
- Pharmaceuticals
- Nutraceuticals
- Food and Beverage
- Animal Nutrition
- Private Equity
Geography
- Spain – HTBA is headquartered in Barcelona, Spain, and operates a manufacturing plant in Murcia, Spain. Regulatory approval for the acquisition is also pending in Spain.
- United States – HTBA has a center of operations in Cincinnati, Ohio, making the U.S. a key geography in its business operations.
Industry
- Pharmaceuticals – The industry is relevant given HTBA's role as a supplier of active forms of vitamin B12 to this sector.
- Nutraceuticals – HTBA provides natural ingredients for nutraceutical products, making this industry classification pertinent.
- Food and Beverage – HTBA supplies ingredients relevant to the food and beverage industry.
- Animal Nutrition – HTBA's role in providing bioactive ingredients for animal nutrition classifies it under this industry.
- Private Equity – Miura Partners' acquisition of HTBA involves private equity investment activities.
Financials
- 475 million euros – The size of the Miura IV fund which facilitated the acquisition.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Miura Partners | Bidding Company | Company | A private equity firm executing the acquisition of HTBA. |
| HealthTech BioActives (HTBA) | Target Company | Company | A leader in the production and marketing of natural ingredients for multiple industries. |
| KPMG | Legal, Financial, Labor, and Fiscal Due Diligence Advisor | Company | Advised Miura Partners during the due diligence phase of the acquisition. |
| Houlihan Lokey | M&A Advisor | Company | Advised Miura Partners on the M&A aspects of the acquisition. |
| Bain & Company | Commercial Due Diligence Advisor | Company | Provided commercial due diligence advisory services for the transaction. |